179 related articles for article (PubMed ID: 28428443)
1. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in
Campbell CT; Haladyna JN; Drubin DA; Thomson TM; Maria MJ; Yamauchi T; Waters NJ; Olhava EJ; Pollock RM; Smith JJ; Copeland RA; Blakemore SJ; Bernt KM; Daigle SR
Mol Cancer Ther; 2017 Aug; 16(8):1669-1679. PubMed ID: 28428443
[TBL] [Abstract][Full Text] [Related]
2. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
Waters NJ; Daigle SR; Rehlaender BN; Basavapathruni A; Campbell CT; Jensen TB; Truitt BF; Olhava EJ; Pollock RM; Stickland KA; Dovletoglou A
J Control Release; 2015 Dec; 220(Pt B):758-65. PubMed ID: 26385168
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
4. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
Richter WF; Shah RN; Ruthenburg AJ
Elife; 2021 Jul; 10():. PubMed ID: 34263728
[TBL] [Abstract][Full Text] [Related]
5. The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
Marcos-Villar L; Nieto A
Sci Rep; 2019 Nov; 9(1):16862. PubMed ID: 31727944
[TBL] [Abstract][Full Text] [Related]
6. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
7. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
8. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Stein EM; Garcia-Manero G; Rizzieri DA; Tibes R; Berdeja JG; Savona MR; Jongen-Lavrenic M; Altman JK; Thomson B; Blakemore SJ; Daigle SR; Waters NJ; Suttle AB; Clawson A; Pollock R; Krivtsov A; Armstrong SA; DiMartino J; Hedrick E; Löwenberg B; Tallman MS
Blood; 2018 Jun; 131(24):2661-2669. PubMed ID: 29724899
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
[TBL] [Abstract][Full Text] [Related]
10. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.
Waters NJ
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):891-901. PubMed ID: 28229434
[TBL] [Abstract][Full Text] [Related]
12. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
13. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R; Lawrence CK; Lakowski TM
J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
[TBL] [Abstract][Full Text] [Related]
14. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
Yi Y; Ge S
J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic strategies for MLL-rearranged leukemias.
Wong NM; So CWE
Biochim Biophys Acta Gene Regul Mech; 2020 Sep; 1863(9):194584. PubMed ID: 32534041
[TBL] [Abstract][Full Text] [Related]
16. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung M; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ
Oncogene; 2019 May; 38(20):3824-3842. PubMed ID: 30670779
[TBL] [Abstract][Full Text] [Related]
17. Targeting critical kinases and anti-apoptotic molecules overcomes steroid resistance in MLL-rearranged leukaemia.
de Groot AP; Saito Y; Kawakami E; Hashimoto M; Aoki Y; Ono R; Ogahara I; Fujiki S; Kaneko A; Sato K; Kajita H; Watanabe T; Takagi M; Tomizawa D; Koh K; Eguchi M; Ishii E; Ohara O; Shultz LD; Mizutani S; Ishikawa F
EBioMedicine; 2021 Feb; 64():103235. PubMed ID: 33581643
[TBL] [Abstract][Full Text] [Related]
18. [Mechanism of A New DOT1L Inhibitor EPZ-5676 and Its Research Progress -Review].
Li LH; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1909-1912. PubMed ID: 28024519
[TBL] [Abstract][Full Text] [Related]
19. DOT1L activity in leukemia cells requires interaction with ubiquitylated H2B that promotes productive nucleosome binding.
Spangler CJ; Yadav SP; Li D; Geil CN; Smith CB; Wang GG; Lee TH; McGinty RK
Cell Rep; 2022 Feb; 38(7):110369. PubMed ID: 35172132
[TBL] [Abstract][Full Text] [Related]
20. MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia.
Itskovich SS; Gurunathan A; Clark J; Burwinkel M; Wunderlich M; Berger MR; Kulkarni A; Chetal K; Venkatasubramanian M; Salomonis N; Kumar AR; Lee LH
Nat Commun; 2020 May; 11(1):2369. PubMed ID: 32398749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]